glp-1 for perimenopause Agonists in Perimenopause: Unique Risks and Potential Opportunities Let’s talk about GLP-1 medications

Faienza et al

eBioscience, California, USA)

Contact: Errol Zhou (Mr.) Tel: +86-551-65523315 Mobile/WhatsApp: +86 17705606359 QQ: 196299583 Skype: [email protected] Email: [email protected] Add: 1002, Huanmao Building, No.105, Mengcheng Road, Hefei City, 230061, China Novo Nordisk recently announced the top-line results of the last two phase IIIa clinical trials (STEP 2, STEP 3) in the phase III STEP project of semaglutide for weight loss

Zhou B, Caudal A, Tang X, Chavez JD, McMillen TS, Keller A, et al

This effect requires GLP-1R expression in brain neurons, as shown in mice lacking GLP-1R in neuron-targeting Wnt1- or nestin-expressing domains ( Glp1r Wnt1/ and Glp1r Nes/ ), and by intracerebroventricular injection of exendin-9-39, a GLP-1R antagonist that suppresses activation of brain GLP-1R signaling